The FDA has granted Priority Review to Sanofi and Regeneron’s supplemental Biologics License Application seeking to expand its blockbuster antibody therapeutic Dupixent (dupilumab) into chronic obstructive pulmonary disease, the companies announced Friday.
Tag Archive for: Sanofi
Merger and acquisition activity is on the rise after the biopharma industry moved on from the COVID-19 pandemic, while the role of AI in drug development is reaching new levels.
Eli Lilly agreed to provide low-cost insulin to patients and donate free insulin to clinics, to settle a lawsuit by Minnesota that accused the three largest insulin makers of deceptively raising the price of the diabetes treatment.
Despite strong sales of its blockbuster drug Dupixent, Sanofi reported that its fourth-quarter 2023 operating income dropped 5% due to a weaker U.S. dollar, high expenses and generic competition.
The agency approved the use of Regeneron and Sanofi’s Dupixent to treat an allergic inflammation of the esophagus in children aged one to 11 years old and weighing at least 15 kg.
The deal will bolster nthye French company’s drug development portfolio with an experimental treatment for a rare genetic disease.
Sanofi is hoping that by sponsoring the Olympic Games it can attract new talent, reward existing staff and shake off the French drugmaker’s conservative image.
The drug makers co-developed the RSV shot for infants and toddlers called Beyfortus, which has already been approved for use in the European Union and United States.
Drugmakers including Pfizer, Sanofi, and Takeda Pharmaceutical plan to raise prices in the United States on more than 500 unique drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors.
Sanofi’s Fexinidazole Winthrop is the first oral treatment for an acute form of sleeping sickness, a lethal parasitic disease transmitted by the bite of infected tsetse flies and found in 36 African countries.